Welcome to our dedicated page for Edwards Lifesciences news (Ticker: EW), a resource for investors and traders seeking the latest updates and insights on Edwards Lifesciences stock.
Edwards Lifesciences Corporation (NYSE: EW) generates frequent news as a structural heart medical device company focused on therapies for complex valve disease and structural heart failure. Company announcements highlight developments across transcatheter aortic valve replacement (TAVR), transcatheter mitral and tricuspid therapies (TMTT), and surgical heart valve technologies, as well as clinical data, regulatory milestones and corporate updates.
News coverage often features clinical trial readouts and registry data for key Edwards platforms, including the SAPIEN TAVR valves, the SAPIEN M3 mitral valve replacement system, and the EVOQUE tricuspid valve replacement system. Releases describe long‑term outcomes from the PARTNER trial series, pivotal ENCIRCLE TMVR results, and real‑world EVOQUE registry findings, with a focus on safety, durability, regurgitation reduction and quality‑of‑life improvements for patients with limited treatment options.
Investors and clinicians can also follow regulatory and guideline‑related updates, such as U.S. Food and Drug Administration approvals for new transcatheter therapies, European CE Mark decisions, and evolving professional society guidelines for aortic, mitral and tricuspid disease management. Corporate news includes earnings releases, financial guidance, share repurchase announcements, participation in major healthcare conferences and leadership transitions disclosed through press releases and 8‑K filings.
In addition, Edwards Lifesciences reports on collaborations and initiatives in the broader cardiovascular ecosystem, such as its founding sponsorship of the American Heart Association’s Heart Valve Initiative. For readers tracking EW news, this mix of clinical, regulatory, financial and partnership updates provides insight into how the company is advancing structural heart therapies and executing its strategy over time.
Edwards Lifesciences (NYSE: EW) announced that Theodora “Doretta” Mistras will become corporate vice president and chief financial officer, effective at the end of May. Mistras succeeds Scott Ullem, who announced his planned transition in October and has served as CFO since 2014. The company highlighted Mistras’ CFO role at Viatris since March 2024, prior senior investment-banking roles, and dual bachelor’s degrees from the University of Pennsylvania and Wharton.
The company said Ullem will support a thoughtful transition and serve as a strategic advisor in the months ahead.
Edwards Lifesciences (NYSE: EW) reported 10-year COMMENCE aortic trial results showing long-term durability of its RESILIA tissue for surgical aortic valves. Key 10-year outcomes: 97.9% freedom from structural valve deterioration, 97.8% freedom from reoperation for SVD, and 98.6% freedom from non-structural valve dysfunction, with sustained hemodynamics. The FDA-approved, pivotal, prospective multicenter study was presented May 2, 2026, at the AATS meeting and supports RESILIA's role in lifetime valve management.
Edwards Lifesciences (NYSE: EW) will present at the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026. Bernard Zovighian, chief executive officer, will take part in a fireside chat at 3:40 p.m. Pacific Time. A live webcast and same-day archived replay will be available on the company investor relations website.
Investors can watch the live stream at the Edwards investor relations site; replay will be posted later the same day.
Edwards Lifesciences (NYSE: EW) reported Q1 2026 sales of $1.65 billion (growth 16.7%; constant currency 12.7%) and Q1 EPS of $0.66 (adjusted EPS $0.78).
Q1 TAVR sales were $1.20 billion (14.4% growth), TMTT sales were $173 million. The company raised FY2026 sales guidance to 9%–11% and adjusted EPS range to $2.95–$3.05, completed a $500 million ASR, and held cash of ≈$2.4 billion.
Edwards Lifesciences (NYSE: EW) will announce operating results for the quarter ended March 31, 2026 after market close on Thursday, April 23, 2026, and will host an earnings conference call at 5:00 p.m. ET that day.
Dial-in numbers: (877) 704-2848 or (201) 389-0893. A live webcast and archived replay will be available in the Investor Relations section at ir.edwards.com.
Edwards Lifesciences (NYSE: EW) reported two-year TRISCEND II results presented at ACC.26 showing sustained benefits with the EVOQUE transcatheter tricuspid valve replacement system. Data showed near elimination of tricuspid regurgitation, improved health status and quality of life, no added device-related risk, and lower all-cause mortality when accounting for patient crossover.
Company noted prior 18-month ESC data and real-world evidence from >1,000 patients in the STS/ACC TVT Registry; EVOQUE is approved in the US and Europe.
Edwards Lifesciences (NYSE: EW) reaffirmed its structural heart leadership and expanded its global health initiative Every Heartbeat Matters, aiming to help 2 million more patients by the end of 2030. The program focuses on increasing diagnosis and treatment access for underserved structural heart patients, especially in low- and middle-income countries. Since 2014, the initiative and partners have impacted more than 4 million patients. The company emphasized innovation, partnerships, and the Edwards Lifesciences Foundation as vehicles to reduce financial, systemic, and geographic barriers to care.
Edwards Lifesciences (NYSE: EW) announced that CFO Scott Ullem will present at two investor conferences in March 2026: Barclays on March 10, 2026 at 10:00 a.m. ET and Leerink on March 11, 2026 at 10:00 a.m. ET.
Live webcasts of both presentations will be available on the company investor relations website, with archived recordings posted later the same day.
Edwards Lifesciences (NYSE: EW) will present at Citi’s Unplugged Medtech and Life Sciences Access Day on February 26, 2026. CFO Scott Ullem is scheduled to present at 10:15 a.m. ET. A live webcast and same‑day archived replay will be available on the company investor relations website.
Investors can access the webcast at the Edwards investor relations site for the presentation and later replay.
Edwards Lifesciences (NYSE: EW) reported Q4 2025 sales of $1.57B (up 13.3%) and Q4 TAVR sales of $1.16B (up 12.0%). FY2025 sales rose 11.5% with full-year TAVR sales of $4.5B. Q4 adjusted EPS was $0.58. The company raised confidence in FY2026 guidance: constant-currency revenue +8–10% and adjusted EPS $2.90–3.05, with TMTT expected to grow 35–45% to $740–780M.
Cash was ~$3.0B and total debt ~$600M. Management cited trial data, guideline updates, new approvals, and product launches as catalysts for 2026 growth.